The historical rank and industry rank for Medigen Vaccine Biologics's Operating Margin % or its related term are showing as below:
ROCO:6547'
s Operating Margin % Range Over the Past 10 Years
Min: -53920.71 Med: -311.54 Max: 29.37
Current: -43.33
ROCO:6547's Operating Margin % is ranked better than 55.83% of 944
companies
in the Biotechnology industry
Industry Median: -86.83
vs ROCO:6547: -43.33
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Medigen Vaccine Biologics Operating Margin % Related Terms
Medigen Vaccine Biologics Operating Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6547 vs VRTX, REGN, ALNY: Operating Margin % Comparison
For the Biotechnology subindustry, Medigen Vaccine Biologics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Vaccine Biologics Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Vaccine Biologics's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Medigen Vaccine Biologics's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Medigen Vaccine Biologics's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigen Vaccine Biologics (ROCO:6547) has a Operating Margin % of -97.27% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Medigen Vaccine Biologics and its competitors. According to the industry distribution chart, Medigen Vaccine Biologics ranks #417 out of 944 companies in the Biotechnology industry, placing it in the top 44.2%.
Is Medigen Vaccine Biologics' Operating Margin % too high?
Medigen Vaccine Biologics' current Operating Margin % is -97.27%. Based on the distribution chart, Medigen Vaccine Biologics ranks #417 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Medigen Vaccine Biologics has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medigen Vaccine Biologics' Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medigen Vaccine Biologics ranks #417 out of 944 companies for Operating Margin %. This puts Medigen Vaccine Biologics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Medigen Vaccine Biologics and its competitors. Medigen Vaccine Biologics's current Operating Margin % is -97.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Vaccine Biologics stock overvalued right now?
Based on GuruFocus' analysis, Medigen Vaccine Biologics (ROCO:6547) is currently considered Possible Value Trap. The stock's GF Value™ is NT$69.49, compared to a current price of NT$45.65 — trading 34.3% below its estimated fair value. The current Operating Margin % is -97.27%. Medigen Vaccine Biologics' overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Medigen Vaccine Biologics (ROCO:6547), the current Operating Margin % is -97.27% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Vaccine Biologics (ROCO:6547) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Vaccine Biologics stock appears to be undervalued.
The current stock price of NT$45.65 is trading 34.3% below its estimated GF Value™ of NT$69.49.
GuruFocus considers Medigen Vaccine Biologics to be Possible Value Trap.
Key valuation signals for ROCO:6547:
Operating Margin %: -97.27%
GF Value™: NT$69.49 vs. price of NT$45.65 (34.3% below fair value)
No single metric tells the full story. See the ROCO:6547 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Vaccine Biologics Corp is engaged in the research, development and wholesale of vaccine and biopharmaceutical, medical devices wholesale and retail, etc. Its products include dengue vaccine, anti-RSV biosimilars, COVID-19 vaccines, enterovirus A71 vaccine, and influenza vaccine QIZ. It operates business only in a single industry in Taiwan.
68GF Score
Get the complete analysis for ROCO:6547
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6547 has been successfully added to your 
